CF-301

BIOLOGICAL2 trials

Sponsors

ContraFect

Conditions

Staphylococcus Aureus BacteremiaStaphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)Staphylococcus Aureus Endocarditis

Phase 1

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

CompletedNCT02439359

ContraFectStaphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)

Start: 2015-05-31End: 2015-12-31Updated: 2020-04-07

Phase 2

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

CompletedNCT03163446

ContraFectStaphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis

Start: 2017-05-23End: 2019-03-07Updated: 2021-10-08

Related Papers

Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity

Journal of Clinical Microbiology2021-04-2916 citations

Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis

Journal of Clinical Investigation2020-04-09118 citations

711. Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)

Open Forum Infectious Diseases2019-10-011 citations

1342. Comparison of Lysin CF-301 (Exebacase) Activity Against S. aureus Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates

Open Forum Infectious Diseases2018-11-013 citations